Wednesday, September 16, 2026
ExploreSearch
Finance Via News

Healthcare Finance

2 articles

FDA Compounding Crackdown Threatens TomorrowsRx Core Revenue as GLP-1 Shortages End

FDA Compounding Crackdown Threatens TomorrowsRx Core Revenue as GLP-1 Shortages End

The FDA is preparing to restrict compounded semaglutide and tirzepatide prescriptions as brand-name supply stabilizes, directly threatening telehealth platforms like TomorrowsRx that built businesses on compound weight-loss medications. The regulatory shift would eliminate the legal pathway these companies use to offer lower-cost alternatives to Ozempic and Mounjaro.

ViaNews Editorial Team (Finance)•
Biotech's Commercial Inflection: What the Gene Therapy and mRNA Pipeline Surge Means for Investors

Biotech's Commercial Inflection: What the Gene Therapy and mRNA Pipeline Surge Means for Investors

The biotechnology sector is approaching a pivotal transition as gene therapy, mRNA, and cell therapy programs simultaneously near commercialization. With major players including Moderna, Regeneron, CRISPR Therapeutics, and REGENXBIO targeting BLA submissions and product launches through 2026–2027, the funding and financing landscape for biotech is shifting from risk capital to revenue-generation models. Investors are watching closely as pipeline assets convert to commercial platforms.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI's 'Show-Me' Reckoning: Earnings Divergence, Executive Exodus, and Regulatory Tightening
Investors are shifting from rewarding AI narratives to demanding tangible results, evidenced by Adobe's weak guidance despite user-growth emphasis, Palantir's stock decline even after winning the Army's TITAN contract, and UiPath's contrasting guidance raise. Simultaneously, high-profile safety-driven departures from Anthropic and Google, plus new regulatory actions (California's under-16 social media ban, Anthropic's misuse-blocking disclosures), signal mounting scrutiny of AI's societal and financial risk profile even as fintech-adjacent funding (Socure) continues.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,288 source documents archived
Query this data → isubstrate.com